How many units of SLU-PP-332 should I draw?

It depends on your vial size, BAC water, and dose. For a 10mg vial with 2mL BAC water, a beginner dose of 10mg is typically 0 units on a U-100 syringe. Use the calculator above for your exact numbers.

How much BAC water should I add to SLU-PP-332?

The standard amount is 2mL of bacteriostatic water for a 10mg vial. More water gives a more dilute solution — easier to measure small doses. Less water means fewer injections per vial. Adjust the BAC water slider in the calculator to see how it changes your syringe units.

How long does a SLU-PP-332 vial last?

At a beginner dose of 10mg daily, a 10mg vial lasts about 1000 doses. The calculator shows exact doses per vial for your selected tier.

What syringe should I use for SLU-PP-332?

Most people use a U-100 insulin syringe (1mL / 100 units). For very small doses, a U-50 or U-30 syringe gives better precision. The calculator adjusts units automatically for whichever syringe you pick.

SLU-PP-332 Dosage Calculator

MetabolicInjectionResearch~4-6 hours half-life

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) developed at Saint Louis University and Washington University School of Medicine.

Exercise mimetic — activates aerobic exercise gene programs without physical activityIncreased fatty acid oxidation by 25% in mouse studiesReduced body weight by 12% in obese mice over 28 days without appetite suppressionImproved exercise endurance — mice ran 45% farther and 70% longer4 weeks on / 4 weeks off

Vial Size

BAC Water (mL)

Dosing Level

10mcg · Daily

Custom Dose (mcg) — optional

Syringe Type

0.2 units

100 units (1mL)

Concentration

5,000

mcg/mL

Draw Volume

0.002

Syringe Units

0.2

units

Doses / Vial

1000

doses

Very small draw (0.2 units) — difficult to measure accurately. Consider using less BAC water for a more concentrated solution.

Try 0.5mL BAC water for an easier-to-measure draw.

Summary: Add 2mL BAC water to your 10mg vial. Draw to 0.2 units on a U-100 syringe for a 10mcg dose. This vial will last 1000 doses.

Cycle Planner

Cycle Length (weeks)

Price Per Vial ($) — optional

Intraperitoneal (animal studies); route for human use not established. Typical beginner frequency: daily.

SLU-PP-332 Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~4-6 hours (estimated from murine PK)

After 1 half-life (5h): 50% remainsAfter 2 half-lives (10h): 25% remainsAfter 3 half-lives (15h): 12.5% remains

At a 25mcg dose: 50% = 13mcg remaining after 5h. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

SLU-PP-332 Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	10mg	Daily
Moderate	25mg	Daily
Aggressive	50mg	Daily

Note: Small-molecule ERR pan-agonist, not a peptide. Preclinical only — all data from mouse studies. Dosed at 50 mg/kg i.p. twice daily in published research. No established human dose exists. Oral bioavailability is under investigation.

About SLU-PP-332

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) developed at Saint Louis University and Washington University School of Medicine. It acts as an "exercise mimetic" — activating the same metabolic gene programs that aerobic exercise normally triggers, without requiring physical activity. In mouse studies, SLU-PP-332 increased energy expenditure, boosted fatty acid oxidation by 25%, and reduced body weight by 12% in diet-induced obese animals over 28 days. Treated mice ran 45% farther and 70% longer than untreated controls. Unlike GLP-1 agonists, SLU-PP-332 does not suppress appetite or reduce food intake. Instead, it works by binding the ligand-binding domain of ERRα and recruiting PGC-1α, driving transcription of genes governing mitochondrial biogenesis and oxidative phosphorylation. All published data come from animal models. No human clinical trials have been initiated, and no safety or efficacy data exist in people. This compound is strictly a research tool at present.

View full SLU-PP-332guide →Add to schedule →